|Articles|July 26, 2002

Flexible light-based system gets FDA nod

TheraLight received clearance from the U.S. Food and Drug Administrationto market its UV120-2 UVA/UUVB Phototherapy System for the treatment ofpsoriasis, vitiligo, atopic dermatitis and seborrheic dermatitis.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME